{"id":95911,"date":"2025-04-15T08:08:01","date_gmt":"2025-04-15T06:08:01","guid":{"rendered":"https:\/\/www.formycon.com\/?page_id=95911"},"modified":"2026-08-18T08:53:45","modified_gmt":"2026-08-18T06:53:45","slug":"fyb202-ustekinumab","status":"publish","type":"page","link":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/","title":{"rendered":"FYB202 Ustekinumab"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;209039&#8243; row_name=&#8221;bla&#8221;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243;][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; equal_height=&#8221;yes&#8221; gutter_size=&#8221;0&#8243; shift_y=&#8221;0&#8243; limit_content=&#8221;&#8221;][vc_column_inner column_width_use_pixel=&#8221;yes&#8221; position_vertical=&#8221;middle&#8221; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;2&#8243; align_mobile=&#8221;align_center_mobile&#8221; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; column_width_pixel=&#8221;800&#8243;][vc_custom_heading text_color=&#8221;color-155072&#8243; heading_semantic=&#8221;h1&#8243; text_size=&#8221;h5&#8243; text_weight=&#8221;700&#8243; text_transform=&#8221;uppercase&#8221; text_space=&#8221;fontspace-210350&#8243; separator_color=&#8221;yes&#8221; separator=&#8221;yes&#8221;]FYB202[\/vc_custom_heading][vc_custom_heading text_color=&#8221;color-186842&#8243; heading_semantic=&#8221;p&#8221; text_weight=&#8221;700&#8243; uncode_shortcode_id=&#8221;100099&#8243; text_color_type=&#8221;uncode-palette&#8221;]Ustekinumab Biosimilar[\/vc_custom_heading][vc_custom_heading heading_semantic=&#8221;p&#8221; text_size=&#8221;h3&#8243; text_weight=&#8221;300&#8243; text_height=&#8221;fontheight-357766&#8243; uncode_shortcode_id=&#8221;358470&#8243;]FYB202 is available as a treatment option for patients with chronic inflammatory diseases in 18 countries worldwide, including the United States, Canada, and various EU member states. Further product launches are planned, including in the MENA region.[\/vc_custom_heading][vc_empty_space empty_h=&#8221;2&#8243;][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row unlock_row_content=&#8221;yes&#8221; row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; mobile_visibility=&#8221;yes&#8221; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;585328&#8243; row_height_pixel=&#8221;600&#8243;][vc_column column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;134115&#8243; back_color_type=&#8221;uncode-palette&#8221;][vc_single_image media=&#8221;97782&#8243; media_width_use_pixel=&#8221;yes&#8221; alignment=&#8221;center&#8221; uncode_shortcode_id=&#8221;368489&#8243; media_width_pixel=&#8221;1400&#8243;][\/vc_column][\/vc_row][vc_row unlock_row_content=&#8221;yes&#8221; row_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; desktop_visibility=&#8221;yes&#8221; medium_visibility=&#8221;yes&#8221; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;513525&#8243;][vc_column column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;134115&#8243; back_color_type=&#8221;uncode-palette&#8221;][vc_single_image media=&#8221;97782&#8243; media_lightbox=&#8221;yes&#8221; media_width_percent=&#8221;100&#8243; alignment=&#8221;center&#8221; uncode_shortcode_id=&#8221;186804&#8243;][\/vc_column][\/vc_row][vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;762269&#8243; row_height_pixel=&#8221;600&#8243;][vc_column column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;581096&#8243; back_color_type=&#8221;uncode-palette&#8221; column_width_pixel=&#8221;1200&#8243;][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; uncode_shortcode_id=&#8221;104467&#8243; limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;189790&#8243; css=&#8221;.vc_custom_1744715179522{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;917321&#8243;]<strong>Indication Area<br \/>\n<\/strong>Immunology[\/vc_column_text][vc_separator sep_color=&#8221;color-jevc&#8221; type=&#8221;dotted&#8221; uncode_shortcode_id=&#8221;105679&#8243; el_width=&#8221;60%&#8221; sep_color_type=&#8221;uncode-palette&#8221;][vc_column_text uncode_shortcode_id=&#8221;919064&#8243;]<strong>Active Ingredient Group<br \/>\n<\/strong>Immunosuppressants \/<br \/>\nInterleukin inhibitors[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;141585&#8243; css=&#8221;.vc_custom_1744715188716{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;800245&#8243;]<strong>Indications of the Reference Drug<br \/>\n<\/strong>Crohn&#8217;s disease, ulcerative colitis, plaque psoriasis, psoriatic arthritis*<strong><br \/>\n<\/strong>[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;208704&#8243; css=&#8221;.vc_custom_1744715197222{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;132579&#8243;]<strong>Market Launch<br \/>\n<\/strong>2025<strong><br \/>\n<\/strong>[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;200910&#8243; css=&#8221;.vc_custom_1744715204142{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;135266&#8243;]<strong>Ustekinumab Market<\/strong><br \/>\nUstekinumab is a well-established and widely used biologic drug for the treatment of chronic inflammatory diseases. Global sales of the reference drug Stelara\u00ae amounted to approximately $6 billion in 2025.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; uncode_shortcode_id=&#8221;104467&#8243; limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;189790&#8243; css=&#8221;.vc_custom_1744715179522{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_separator sep_color=&#8221;color-jevc&#8221; type=&#8221;dotted&#8221; uncode_shortcode_id=&#8221;205982&#8243; el_width=&#8221;100%&#8221; sep_color_type=&#8221;uncode-palette&#8221;][vc_column_text uncode_shortcode_id=&#8221;176429&#8243;]<b>Commercialization partners:<\/b>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; uncode_shortcode_id=&#8221;104467&#8243; limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;189790&#8243; css=&#8221;.vc_custom_1744715179522{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;105944&#8243;]<strong><img decoding=\"async\" class=\"alignnone size-full wp-image-96057\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/FK.png\" alt=\"\" width=\"153\" height=\"40\" srcset=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/FK.png 153w, https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/FK-150x40.png 150w\" sizes=\"(max-width: 153px) 100vw, 153px\" \/><br \/>\n<\/strong><strong>Brand:<\/strong> Otulfi\u00ae<br \/>\n<strong>Region:<\/strong> Key global markets[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;141585&#8243; css=&#8221;.vc_custom_1744715188716{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;116936&#8243;]<strong><img decoding=\"async\" class=\"alignnone wp-image-97807 size-full\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/09\/Teva_Logo_180x40.png\" alt=\"\" width=\"180\" height=\"40\" \/><br \/>\n<\/strong><strong>Brand:<\/strong> Fymskina\u00ae<br \/>\n<strong>Region:<\/strong> Germany[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;208704&#8243; css=&#8221;.vc_custom_1744715197222{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;181127&#8243;]<strong><img decoding=\"async\" class=\"alignnone size-full wp-image-97801\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/09\/MSPharma_Logo_180x40.png\" alt=\"\" width=\"180\" height=\"40\" \/><br \/>\n<\/strong><strong>Brand:<\/strong> Sitovab\u00ae<br \/>\n<strong>Region:<\/strong> MENA<\/p>\n<p><strong>\u00a0<\/strong>[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;200910&#8243; css=&#8221;.vc_custom_1744715204142{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;116701&#8243;]<strong><img decoding=\"async\" class=\"alignnone wp-image-100778 size-full\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2026\/08\/Everex_Logo_180x40.png\" alt=\"\" width=\"180\" height=\"40\" \/><br \/>\n<\/strong><strong>Brand:<\/strong> N.N.<br \/>\n<strong>Region:<\/strong> Parts of LATAM<\/p>\n<p><strong>\u00a0<\/strong>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; position_vertical=&#8221;bottom&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;183068&#8243;][vc_separator sep_color=&#8221;&#8221; uncode_shortcode_id=&#8221;149492&#8243;][vc_column_text text_lead=&#8221;small&#8221; uncode_shortcode_id=&#8221;150708&#8243;]<\/p>\n<div style=\"text-align: right;\">* The specific indication groups approved are listed in the product information<br \/>\nprovided by the EMA or FDA.<\/div>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row unlock_row_content=&#8221;yes&#8221; row_height_percent=&#8221;25&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;0&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; back_color=&#8221;color-200069&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; mobile_visibility=&#8221;yes&#8221; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;118803&#8243; row_height_pixel=&#8221;200&#8243; back_color_type=&#8221;uncode-palette&#8221;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;350506&#8243;][vc_single_image media=&#8221;97738&#8243; media_width_percent=&#8221;100&#8243; alignment=&#8221;center&#8221; uncode_shortcode_id=&#8221;991364&#8243;][\/vc_column][\/vc_row][vc_row unlock_row_content=&#8221;yes&#8221; row_height_percent=&#8221;25&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;0&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; back_color=&#8221;color-200069&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; mobile_visibility=&#8221;yes&#8221; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;202553&#8243; row_height_pixel=&#8221;200&#8243; back_color_type=&#8221;uncode-palette&#8221;][vc_column column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;879127&#8243;][vc_empty_space empty_h=&#8221;4&#8243;][vc_custom_heading text_color=&#8221;color-186842&#8243; heading_semantic=&#8221;p&#8221; text_weight=&#8221;700&#8243; uncode_shortcode_id=&#8221;116480&#8243; text_color_type=&#8221;uncode-palette&#8221;]FYB202 Biosimilar Development[\/vc_custom_heading][vc_empty_space empty_h=&#8221;4&#8243;][\/vc_column][\/vc_row][vc_row unlock_row_content=&#8221;yes&#8221; row_height_percent=&#8221;100&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;0&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; desktop_visibility=&#8221;yes&#8221; medium_visibility=&#8221;yes&#8221; auto_height_device=&#8221;yes&#8221; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;447782&#8243;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;350506&#8243;][vc_single_image media=&#8221;96109&#8243; media_width_percent=&#8221;100&#8243; alignment=&#8221;center&#8221; uncode_shortcode_id=&#8221;209157&#8243;][\/vc_column][\/vc_row][vc_row unlock_row_content=&#8221;yes&#8221; row_height_percent=&#8221;100&#8243; back_color=&#8221;color-200069&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; desktop_visibility=&#8221;yes&#8221; medium_visibility=&#8221;yes&#8221; auto_height_device=&#8221;yes&#8221; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;801105&#8243; back_color_type=&#8221;uncode-palette&#8221;][vc_column column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;879127&#8243;][vc_custom_heading text_color=&#8221;color-186842&#8243; heading_semantic=&#8221;p&#8221; text_size=&#8221;h4&#8243; text_weight=&#8221;700&#8243; uncode_shortcode_id=&#8221;143297&#8243; text_color_type=&#8221;uncode-palette&#8221;]FYB202 Biosimilar Development[\/vc_custom_heading][\/vc_column][\/vc_row][vc_row row_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;185374&#8243;][vc_column column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;102763&#8243; column_width_pixel=&#8221;800&#8243;][vc_empty_space empty_h=&#8221;3&#8243; mobile_visibility=&#8221;yes&#8221;][vc_accordion typography=&#8221;yes&#8221; gutter_simple=&#8221;0&#8243; uncode_shortcode_id=&#8221;605931&#8243; el_id=&#8221;devdetails&#8221; el_class=&#8221;devdetails&#8221; active_tab=&#8221;0&#8243;][vc_accordion_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;FYB202 (Ustekinumab) Mode of Action&#8221; tab_id=&#8221;1730916296154-2-101744699040478&#8243;][vc_row_inner limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;183589&#8243;][vc_custom_heading heading_semantic=&#8221;p&#8221; text_size=&#8221;custom&#8221; text_weight=&#8221;700&#8243; text_transform=&#8221;uppercase&#8221; text_height=&#8221;fontheight-179065&#8243; text_space=&#8221;fontspace-210350&#8243; separator_color=&#8221;yes&#8221; separator=&#8221;yes&#8221; sub_lead=&#8221;yes&#8221; sub_reduced=&#8221;yes&#8221; subheading=&#8221;Ustekinumab is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23 and is used to treat various serious inflammatory diseases such as moderate to severe psoriasis. In 2016, its therapeutic range was expanded to include the treatment of Crohn&#8217;s disease and, in 2019, ulcerative colitis, both of which are chronic inflammatory bowel diseases. The drug is also used to treat psoriatic arthritis.&#8221; uncode_shortcode_id=&#8221;193206&#8243; heading_custom_size=&#8221;24px&#8221;]How does FYB202 (Ustekinumab) work?[\/vc_custom_heading][vc_column_text text_lead=&#8221;yes&#8221; uncode_shortcode_id=&#8221;142771&#8243;]<\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/overview\/otulfi-epar-medicine-overview_en.pdf\" target=\"_blank\" rel=\"noopener\">Further Information<\/a><\/p>\n<p>[\/vc_column_text][vc_empty_space empty_h=&#8221;2&#8243;][\/vc_column_inner][\/vc_row_inner][\/vc_accordion_tab][vc_accordion_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;Development and Commercialization Milestones&#8221; tab_id=&#8221;1730790947-1-351744699040478&#8243;][vc_row_inner limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;188630&#8243;][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;243008&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">June 2025<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Teva subsidiary Ratiopharm becomes secondary commercialization partner for FYB202\/Fymskina\u00ae in Germany<\/span>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;115752&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">May 2025<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Commercial Launch of FYB202\/Otulfi\u00ae in Canada<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-and-fresenius-kabi-announce-the-commercial-launch-of-fyb202-otulfi-an-approved-ustekinumab-biosimilar-in-canada\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;147568&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">March 2025<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Commercial Launch of FYB202\/Otulfi\u00ae in the U.S. and the E.U.<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/fyb202-otulfi-ustekinumab-aauz-a-biosimilar-to-stelara-launched-in-the-united-states-and-the-european-union\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;126698&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">January 2025<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Approval in the UK<br \/>\n<\/span><a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-and-fresenius-kabi-announce-mhra-approval-for-fyb202-otulfi-ustekinumab-a-biosimilar-to-stelara\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;186359&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">January 2025<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Approval in Canada<br \/>\n<\/span><a href=\"&quot;https:\/\/www.formycon.com\/blog\/press-release\/formycon-und-fresenius-kabi-canada-erhalten-zulassung-von-health-canada-fuer-fyb202-otulfi-ustekinumab-ein-biosimilar-zu-stelara\/\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;761298&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">December 2024<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">MS Pharma becomes commercialization partner for the MENA Region<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/ms-pharma-becomes-partner-for-the-commercialization-of-fyb202-ustekinumab-in-the-mena-region\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;170176&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">September 2024<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">FYB202 Approval in the U.S.<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-and-fresenius-kabi-receive-fda-approval-for-fyb202-otulfi-ustekinumab-aauz\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;155191&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">September 2024<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">FYB202 Approval in the E.U.<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-and-fresenius-kabi-receive-european-commission-approval-for-fyb202-otulfi-ustekinumab-for-the-treatment-of-serious-inflammatory-diseases\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;359602&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">July 2024<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Positive CHMP opinion for the E.U. marketing authorization of FYB202<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-and-fresenius-kabi-receive-positive-chmp-opinion-for-fyb202\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;626227&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">March 2024<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Settlement agreement with Johnson &amp; Johnson for Europa and Canada<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-and-fresenius-kabi-reach-settlement-agreement-for-ustekinumab-biosimilar-candidate-fyb202-in-europe-and-canada\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;467535&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">November 2023<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">File acceptance by the U.S. Food and Drug Administration (FDA)<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/file-acceptance-fyb202\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;889067&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">September 2023<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Acceptance of the Marketing Authorization Application by the EMA<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-and-fresenius-kabi-announce-european-medicines-agency-acceptance-of-the-marketing-authorization-application-for-fyb202-an-ustekinumab-biosimilar-candidate\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;697909&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">August 2023<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Settlement agreement with Johnson &amp; Johnson for FYB202 in the U.S.<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/fyb202-settlement-agreement-us\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;234419&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">April 2023<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Successful completion of clinical development of FYB202<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-announces-successful-results-of-phase-i-clinical-trial-for-ustekinumab-biosimilar-candidate-fyb202-and-concludes-clinical-development\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;178455&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">February 2023<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Global commercialization partnership with Fresenius Kabi<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-and-fresenius-kabi-conclude-global-commercialization-partnership-for-fyb202\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;213735&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">August 2022<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Positive interim results from Phase III study<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycons-biosimilar-ustekinumab-candidate-fyb202-shows-comparable-efficacy-to-reference-product-stelara-in-phase-iii-study\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;385011&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">March 2022<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Formycon acquires full rights of FYB202 in a transaction with ATHOS KG<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-is-acquiring-the-biosimilar-assets-fyb201-and-fyb202-and-strengthening-its-position-in-the-global-growth-market-of-biosimilars-through-long-term-partnership-with-athos-kg\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;534056&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">November 2020<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Start of clinical Phase III Study<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-and-bioeq-announce-launch-of-phase-iii-study-of-fyb202-a-biosimilar-candidate-for-stelarar-ustekinumab\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;199716&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">October 2019<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Start of clinical Phase I Study<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-announces-start-of-phase-i-clinical-trial-with-ustekinumab-biosimilar-candidate-fyb202\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;313457&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">December 2017<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Formycon and Aristo Pharma establish joint venture for the development of FYB202<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-and-aristo-pharma-are-founding-a-joint-venture-for-the-development-of-fyb202-2\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;115737&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">May 2017<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Disclosure of the reference for FYB202<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-announces-details-of-further-pipeline-product-fyb202-is-a-biosimilar-candidate-for-stelara-ustekinumab\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][\/vc_column_inner][\/vc_row_inner][\/vc_accordion_tab][vc_accordion_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;Scientific Publications on FYB202&#8243; tab_id=&#8221;1730790947-2-501744699040478&#8243;][vc_row_inner limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;693360&#8243;][vc_custom_heading heading_semantic=&#8221;p&#8221; text_size=&#8221;custom&#8221; text_weight=&#8221;700&#8243; text_transform=&#8221;uppercase&#8221; text_height=&#8221;fontheight-179065&#8243; text_space=&#8221;fontspace-210350&#8243; separator_color=&#8221;yes&#8221; separator=&#8221;yes&#8221; sub_lead=&#8221;yes&#8221; sub_reduced=&#8221;yes&#8221; subheading=&#8221;Data on the comparability of the biosimilar FYB202 with the reference drug were published in several poster presentations and in a scientific article.&#8221; uncode_shortcode_id=&#8221;148917&#8243; heading_custom_size=&#8221;24px&#8221;]Preclinical ans clinical Data[\/vc_custom_heading][vc_empty_space empty_h=&#8221;2&#8243;][vc_gallery el_id=&#8221;gallery-130684&#8243; type=&#8221;carousel&#8221; medias=&#8221;95994,95992,95990,96054&#8243; carousel_lg=&#8221;3&#8243; carousel_md=&#8221;2&#8243; carousel_sm=&#8221;1&#8243; gutter_size=&#8221;3&#8243; media_items=&#8221;media|custom_link|original,description,icon,caption&#8221; carousel_interval=&#8221;3000&#8243; carousel_navspeed=&#8221;400&#8243; carousel_loop=&#8221;yes&#8221; stage_padding=&#8221;0&#8243; single_overlay_opacity=&#8221;50&#8243; single_padding=&#8221;2&#8243; uncode_shortcode_id=&#8221;153254&#8243; single_link=&#8221;url:https%3A%2F%2Fwww.formycon.com%2Funternehmen%2Fkontakt%2F|title:Kontakt&#8221; items=&#8221;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&#8221;][vc_empty_space empty_h=&#8221;2&#8243;][\/vc_column_inner][\/vc_row_inner][\/vc_accordion_tab][\/vc_accordion][\/vc_column][\/vc_row][vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;762269&#8243; row_height_pixel=&#8221;600&#8243;][vc_column column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;372897&#8243; column_width_pixel=&#8221;1200&#8243;][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; limit_content=&#8221;&#8221; uncode_shortcode_id=&#8221;149764&#8243; css=&#8221;.vc_custom_1757693219486{padding-right: 112px !important;}&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; position_vertical=&#8221;bottom&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;745787&#8243;][vc_empty_space empty_h=&#8221;2&#8243;][vc_column_text text_lead=&#8221;small&#8221; uncode_shortcode_id=&#8221;999486&#8243;]<\/p>\n<div style=\"text-align: right;\">Stelara\u00ae is a registered trademark of Johnson &amp; Johnson<br \/>\nOtulfi\u00ae is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries<\/div>\n<div style=\"text-align: right;\">Fymskina\u00ae is a registered trademark of Formycon AG<\/div>\n<div style=\"text-align: right;\">Sitovab\u00ae is a registered trademark of MS Pharma<\/div>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;209039&#8243; row_name=&#8221;bla&#8221;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; [&hellip;]<\/p>\n","protected":false},"author":23,"featured_media":81334,"parent":78082,"menu_order":4,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-95911","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FYB202 Ustekinumab - Formycon AG<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FYB202 Ustekinumab - Formycon AG\" \/>\n<meta property=\"og:description\" content=\"[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;209039&#8243; row_name=&#8221;bla&#8221;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/\" \/>\n<meta property=\"og:site_name\" content=\"Formycon AG\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-18T06:53:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/09\/fyb202-formycon-keyvisual-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1600\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.formycon.com\\\/en\\\/biosimilars\\\/fyb202-ustekinumab\\\/\",\"url\":\"https:\\\/\\\/www.formycon.com\\\/en\\\/biosimilars\\\/fyb202-ustekinumab\\\/\",\"name\":\"FYB202 Ustekinumab - Formycon AG\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.formycon.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.formycon.com\\\/en\\\/biosimilars\\\/fyb202-ustekinumab\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.formycon.com\\\/en\\\/biosimilars\\\/fyb202-ustekinumab\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.formycon.com\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/fyb202-formycon-keyvisual-1.jpg\",\"datePublished\":\"2025-04-15T06:08:01+00:00\",\"dateModified\":\"2026-08-18T06:53:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.formycon.com\\\/en\\\/biosimilars\\\/fyb202-ustekinumab\\\/#breadcrumb\"},\"inLanguage\":\"en\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.formycon.com\\\/en\\\/biosimilars\\\/fyb202-ustekinumab\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en\",\"@id\":\"https:\\\/\\\/www.formycon.com\\\/en\\\/biosimilars\\\/fyb202-ustekinumab\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.formycon.com\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/fyb202-formycon-keyvisual-1.jpg\",\"contentUrl\":\"https:\\\/\\\/www.formycon.com\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/fyb202-formycon-keyvisual-1.jpg\",\"width\":1600,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.formycon.com\\\/en\\\/biosimilars\\\/fyb202-ustekinumab\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.formycon.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biosimilars\",\"item\":\"https:\\\/\\\/www.formycon.com\\\/en\\\/biosimilars\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"FYB202 Ustekinumab\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.formycon.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.formycon.com\\\/en\\\/\",\"name\":\"Formycon AG\",\"description\":\"Global Quality Biosimilars\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.formycon.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FYB202 Ustekinumab - Formycon AG","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/","og_locale":"en_US","og_type":"article","og_title":"FYB202 Ustekinumab - Formycon AG","og_description":"[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;209039&#8243; row_name=&#8221;bla&#8221;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; [&hellip;]","og_url":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/","og_site_name":"Formycon AG","article_modified_time":"2026-08-18T06:53:45+00:00","og_image":[{"width":1600,"height":800,"url":"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/09\/fyb202-formycon-keyvisual-1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/","url":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/","name":"FYB202 Ustekinumab - Formycon AG","isPartOf":{"@id":"https:\/\/www.formycon.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/#primaryimage"},"image":{"@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/#primaryimage"},"thumbnailUrl":"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/09\/fyb202-formycon-keyvisual-1.jpg","datePublished":"2025-04-15T06:08:01+00:00","dateModified":"2026-08-18T06:53:45+00:00","breadcrumb":{"@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/#breadcrumb"},"inLanguage":"en","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/"]}]},{"@type":"ImageObject","inLanguage":"en","@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/#primaryimage","url":"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/09\/fyb202-formycon-keyvisual-1.jpg","contentUrl":"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/09\/fyb202-formycon-keyvisual-1.jpg","width":1600,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb202-ustekinumab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.formycon.com\/en\/"},{"@type":"ListItem","position":2,"name":"Biosimilars","item":"https:\/\/www.formycon.com\/en\/biosimilars\/"},{"@type":"ListItem","position":3,"name":"FYB202 Ustekinumab"}]},{"@type":"WebSite","@id":"https:\/\/www.formycon.com\/en\/#website","url":"https:\/\/www.formycon.com\/en\/","name":"Formycon AG","description":"Global Quality Biosimilars","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.formycon.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-09-11 06:23:37","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"translation_priority","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/95911","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/users\/23"}],"replies":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/comments?post=95911"}],"version-history":[{"count":8,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/95911\/revisions"}],"predecessor-version":[{"id":100819,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/95911\/revisions\/100819"}],"up":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/78082"}],"wp:attachment":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/media?parent=95911"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}